Please read and agree to the terms and conditions of this site.
@xconomy.com 4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com 5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com 5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com 5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@venturebeat.com 6 years ago
Menlo Ventures banks on tech-driven life sciences, adds Greg Yap as new partner